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Abstract
Although there is a great deal of interest in the role played by tumor-associated macrophages in tumor progression, the
knowledge of the biological mediators involved in the interplay between macrophages and tumor cells is still limited. In the
present study, we investigated whether the lipoxygenase pathway in resident murine peritoneal macrophages is affected by
contact with tumor cells of a different origin, e.g. murine B16 melanoma and L929 fibrosarcoma cells, and human Hs294T
melanoma and HT1080 fibrosarcoma cells. Our experiments have been carried out by using macrophages co-cultivated with
tumor cells at different ratios, in order to simulate the relative proportions between macrophages and tumor cells during the
in vivo development of a tumor. Reverse phase HPLC analyses of the lipoxygenase products of resident peritoneal
macrophages revealed a rather complex profile characterized by a high level of 12(S)-hydroxyeicosatetraenoic acid and
15(S)-hydroxyeicosatetraenoic acid followed by leukotriene B4, 5(S)-hydroxyeicosatetraenoic acid, and lipoxins.
Macrophages co-cultivated with tumor cells, both murine and human, showed a marked reduction of lipoxygenase
products, mainly in the co-cultures where tumor cells prevailed over macrophages. The characteristic profile of macrophage
lipoxygenase products was re-established after removal of tumor cells from the co-cultures. The inhibitory effect on
lipoxygenase pathways exerted by tumor cells, was not seen when macrophages were co-cultivated with normal primary
murine and human fibroblasts.
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Tumors contain various amounts of inflamma-
tory cells, and a certain percentage of these cells
are represented by macrophages, the so-called
tumor-associated macrophages [1]. An anti-tumoral
role has generally been attributed to tumor-
associated macrophages [2–4], but there are also
reports that they favor, rather than retard, tumor
growth and invasiveness [5–10]. The contrasting
effects of macrophages on tumor progression has
not been clarified although they might be related to
the different amounts of macrophages in the
tumoral mass at various stages of tumor growth.
A large number of macrophages contributes to the
tumoral mass during the early phase of tumor
growth, while the number of infiltrating macro-
phages declines during the development of tumor
mass [11–13]. It is conceivable that the different
degrees of contact between macrophages and tumor
cells during the different stages of tumor growth
are relevant to the host cell/tumor cell relationship.
Upon contact with tumor cells, macrophages
release a range of mediators, including tumor
necrosis factor a [14,15], nitric oxide [16,17],
prostaglandin E2 [15,18,19]. While nitric oxide and
tumor necrosis factor a are cytotoxic for tumor
cells [20,21], prostaglandin E2 facilitates the escape
of tumors from immune control by inhibiting T
lymphocyte and macrophage activities [22].
To our knowledge, changes in the lipoxygenase
pathway in macrophages upon contact with tumorTable 1
Lipoxygenase products synthesized by macrophage cultures and by macro
Lipoxygenase
products









LXsb 3.8c 2.0 2.3
trans-LTB4
d 16.6 10.3 13.7
LTB4 14 17.5 16.2 1
15(S)-HETE 43 34.3 42.2 3
12(S)-HETEe 210.5 215 250.2 18
a All co-cultures contained macrophages and melanoma cells at 1:1 rati
b LXs represent the sum of LXA4, LXB4 and their trans isomers.
c Values are ng/106 macrophages.
d trans-LTB4 represent the sum of 6-trans-LTB4 and 6-trans-12-epi-LT
e The profile of the lipoxygenase products also contained very small qucells have not yet been explored. In the present
study, we investigated whether synthesis of lipoxy-
genase products in macrophages is affected by
contact with tumor cells. Our experimental model
consisted in resident murine peritoneal macro-
phages co-cultivated with murine B16 melanoma
cells at different ratios in order to reproduce the
relative proportions between tumor cells and
macrophages at different times of tumor growth
[11–13]. In our experimental protocol, we also
included other types of tumor cells, such as murine
L929 fibrosarcoma cells, human Hs294T melanoma
and HT1080 fibrosarcoma cells. Moreover, we
performed experiments by using macrophages co-
cultivated with normal fibroblasts derived from
murine and human primary cultures, in order to
ascertain whether the changes in lipoxygenase
activity induced by tumor cells represents a
tumor-specific rather than a tumor-associated
phenomenon.2. Materials and methods
2.1. Cells and culture conditions
In the present study, we used the murine B16-
F10 melanoma (clone F10-M3, [23]) and L929
fibrosarcoma cells (kindly donated by Dr Dello
Sbarba, Department of Experimental Pathology and
Oncology, University of Florence), human Hs294T
melanoma and HT1080 fibrosarcoma cellsphages co-cultivated with F10-M3 melanoma cells









1.9 1.9 – –
5.9 10.5 4.2 –
4.1 20.1 5.7 –
1.6 45.1 13.5 22.8
3.5 198.6 41.3 47.6
o.
B4.
antity of 5(S)-HETE, that was not reported in the Table.
Table 2
Lipoxygenase products synthesized by macrophage cultures and by









LXsd 2.0e 1.3 – –
Trans-LTB4
f 13.1 5.3 – –
LTB4 22.8 7.9 – –
15(S)-HETE 67.1 40.4 26.3 28.7
12(S)-HETE 372.2 177.3 76.7 56.9
a Cellular density in the various cell cultures: 200,000 cells/cm2.
b The viability of macrophages in the different co-cultures, as
evaluated by determining the release of nitric oxide into growth
media [27], was found to be unaffected by culture conditions.
c Macrophage:tumor cell ratio in the co-culture.
d LXs represent the sum of LXA4, LXB4 and their trans isomers.
e Values are ng/106 macrophages.
f trans-LTB4 represent the sum of 6-trans-LTB4 and 6-transK12-
epi-LTB4.
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used primary cultures of murine fibroblasts isolated
in our laboratory from C57Bl/6 mice, and human
skin fibroblasts (donated by Dr Monti, Department.
of Experimental Pathology and Oncology, Univer-
sity of Florence). Cells were cultivated in Dulbec-
co’s Modified Eagle Medium (DMEM 4500,
GIBCO) supplemented with 10% fetal calf serum
(FCS) (Boerhinger Mannheim, Germany), at 37 8C
in a 10% CO2 humidified atmosphere. Cells were
propagated using a solution of trypsin-EDTA.Table 3
Lipoxygenase activity in macrophage coltures upon the removal of tumor
Culture Lipoxygenase product
LXsb trans-LT
Macrophage culture 1.6d 7.7
Macrophage:tumor cell co-culture – –
Macrophages freed from tumor cellse 2.1 11.8
a Cellular density in the various macrophage:tumor cell cultures: 200,0
b LXs represent the sum of LXA4, LXB4 and their trans isomers.
c trans-LTB4 represent the sum of 6-trans-LTB4 and 6-trans-12-epi-LT
d Values are ng/106 macrophages.
e Tumor cells were removed from macrophage:tumor cell co-culture im
trypsin-EDTA solution.2.2. Preparation of co-cultures of macrophages
with tumor cells or normal cells
Cultures of resident macrophages were established
from lavages of the peritoneal cavities of 6–8 week old
C57Bl/6 mice, as described in a previous paper [24].
In our experiments, we used: (a) macrophage cultures
at different densities; (b) macrophage:tumor cell co-
cultures at a 1:1 ratio, but at different cell densities;
(c) high density macrophage:tumor cell co-cultures at
different ratios (from 4:1 to 1:4); (d) high density
macrophage:normal cell co-cultures at 1:1 ratio.
Macrophage cultures and co-cultures were maintained
for 18 h in a medium containing 250 mg/ml BSA, at
37 8C, in a 10% CO2 humidified atmosphere.2.3. Analysis of lipoxygenase products
The analysis of lipoxygenase products were per-
formed on cultures which were incubated at 37 8C for
20 min with arachidonic acid (20 mM) and calcium
ionophore A23187 (5 mM) in a pre-warmed PBS
solution at pH 7.45 containing CaCC (1.0 mM) and
MgCC (0.8 mM) chlorides. The reaction was stopped
by adding 2 volumes of cold methanol containing
100 ng of PGB2, as internal standard, transferred into
plastic tubes and mantained for 2 h in ice. After
precipitation of the proteinaceus material by centrifu-
gation, the reaction mixture was transferred into round-
bottom flasks and evaporated under vacuum. The
residue was resuspended in 10 ml of methanol–H2O
(1:45; vol:vol) by vortexing, acidified to pH 3.5 withcellsa
s
B4




00 cells/cm2; ratio of macrophage to tumor cells: 1:4.
B4.
mediately before analysis of lipoxygenase products, by the use of
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phase cartridge (C18 Plus Sep-Pak, Waters Associ-
ates). The cartridge was eluted with n-hexane followed
by methyl formate and methanol. The methyl formate
fraction containing LTB4, LXs, and monoHETEs, was
evaporated under a stream of nitrogen and the residue,
resuspended in a small volume of methanol, was
chromatographed on a LiChrospher 100 RP-18 columnFig. 1. RP-HPLC profiles of lipoxygenase products synthetized by murin
macrophages (B). (1: trans-LXB4, 2: LXB4; 3: trans-LXA4; 4: LXA4; 5: P
HETE; 10: 12(S)-HETE; 11: 5(S)-HETE).(4.6 mm!25 cm, 5-mm particles, LiChroCART,
Merck) mounted in a Perkin Elmer, Model 250,
HPLC apparatus. Chromatography was performed at
room temperature by using a 19 min isocratic elution in
solvent A (methanol:H2O:acetic acid; 65:35:0.01, v/v),
followed by a 1 min linear gradient from 100% solvent
A to 100% solvent B (methanol:H2O:acetic acid;
75:25:0.01, v/v), and a 40 min isocratic elution ine F10-M3 melanoma cells* (A) and by resident murine peritoneal
GB2; 6: 6-trans-LTB4; 7: 6-transK12-epi-LTB4; 8: LTB4; 9:15(S)-
Fig. 2. RP-HPLC profiles of leukotrienes produced by resident murine peritoneal macrophages (A), by macrophage: murine fibroblast co-
cultures (B), by macrophage:murine L929 fibrosarcoma cell co-cultures (C). Cellular density in the cultures were 150,000 cells/cm2; ratio in co-
cultures was 1:1. In our experimental conditions murine fibroblasts and fibrosarcoma cells showed no generation of leukotrienes.
Chromatography were performed at room temperature using a 40 min isocratic elution in 100% solvent B. (1: PGB2; 2: 6-trans-LTB4; 3: 6-
trans-12-epi-LTB4; 4: LTB4).
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run. The effluents were analyzed with a photodiode
array rapid spectral detector (Model 235, Perkin
Elmer). Lipoxygenase products in the chromato-
grams were identified by comparison with authentic
standards and verified by spectra analysis [25,26].
The levels of lipoxygenase products were deter-
mined by the use of calibration curves constructed
with authentic standards, and the values were
corrected by the recovery of the PGB2.
Data reported in Tables 1–3, Figs. 2 and 3 derived
from a representative experiment of 3–4.3. Results
Fig. 1 gives the RP-HPLC profile of lipoxygenase
products synthesized by cultures of B16 melanoma
cells and murine resident peritoneal macrophages.
The profile of lipoxygenase products of macrophage
cultures was characterized by high levels of 12-HETE
and 15-HETE, followed by LTB4, 5-HETE, and LXs.
In our experimental conditions tumor cells showed no
generation of lipoxygenase products. Table 1 presents
the profile of lipoxygenase products of macrophages
co-cultivated with tumor cells at a 1:1 ratio comparedwith that of macrophage cultures. Macrophage
cultures at different densities generated comparable
amounts of lipoxygenase products. Macrophage:tu-
mor cell co-cultures at low densities synthesized the
same amount of lipoxygenase products as those found
in macrophage cultures. On the other hand, a marked
reduction of HETEs, accompanied by a lack of LTB4
and LXs, was found in high density co-cultures
(200.000 cells/cm2). Table 2 gives the profiles of
lipoxygenase products generated by macrophages co-
cultivated with tumor cells at different ratios.
The reduction of lipoxygenase products found in 1:1
macrophage:tumor cell co-cultures was still more
evident in 1:4 co-cultures, while in 4:1 co-cultures this
reduction was rather limited. As shown in Table 3,
macrophage lipoxygenase activity promptly recov-
ered after tumor cells were removed from the co-
cultures.
As shown in Fig. 2, co-cultivation with L929
fibrosarcoma cells also inhibited macrophage leuko-
triene production, which, however, was not affected
by the presence of murine skin fibroblasts. A similar
different effect was found in leukotriene synthesis in
macrophages co-cultivated with human tumoral
(Hs294T melanoma and HT1080 fibrosarcoma cells)
and normal fibroblasts (Fig. 3).
Fig. 3. RP-HPLC profiles of leukotrienes produced by resident murine peritoneal macrophages (A), by macrophage:human fibroblast co-
cultures (B), by macrophage:human Hs294T melanoma cell co-cultures (C), by macrophage:human HT1080 fibrosarcoma cell co-cultures
(D). Cellular density in the cultures were 150, 000 cells/cm2; ratio in co-cultures was 1:1. In our experimental conditions human fibroblasts and
tumor cells showed no generation of leukotrienes. Chromatography were performed at room temperature using a 40 min isocratic elution in
100% solvent B. (1: PGB2; 2: 6-trans-LTB4; 3: 6-transK12-epi-LTB4; 4: LTB4).
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Using an experimental model represented by
macrophages cultivated together with tumor cells at
different ratios, we sought to explore the extent to
which lipoxygenase activity of macrophages in the
tumor mass is influenced by contact with tumor cells.
Data obtained by using our experimental model
indicated that the lipoxygenase pathway in macro-
phages is inhibited upon contact with tumor cells.
Under the same experimental conditions, tumor cells
did not generate lipoxygenase products. We alsofound that the subtraction of arachidonic acid from the
reaction mixture by tumor cells was negligible (data
not shown), an observation that appears to rule out
that the decreased synthesis of lipoxygenase products
in macrophages co-cultivated with tumor cells is due
to metabolic competition between macrophages and
tumor cells.
Two interacting variables proved to be critical for
the inhibition of lipoxygenase activity in macrophages
co-cultivated with tumor cells: high cell density and
low macrophage:tumor cell ratio. It is possible that
these variables provide a tight contact between
L. Calorini et al. / Cancer Letters 223 (2005) 151–158 157macrophages and tumor cells, a condition that might
occur in late stages of tumor growth. The inhibition of
lipoxygenase activity induced by tumor cells on
macrophages appeared to be a reversible phenomenon
since this activity was completely recovered after
tumor cells were removed from the co-cultures. The
fact that lipoxygenase activity was not modified in
macrophages grown in media conditioned by tumor
cells strengthens the requirement of a tight contact
between the two cell types in order to inhibit
macrophage lipoxygenase activity (data not shown).
The tumor-inhibiting effect on macrophage lipoxy-
genase activity appeared to be a tumor-specific
phenomenon, in view of the findings that macrophage
lipoxygenase activity was inhibited by human or
murine melanoma and fibrosarcoma cells, but not by
normal human or murine fibroblasts.
The inhibitory effect of tumor cells on the
lipoxygenase activity of macrophages might be
important in tumor progression due to the depletion
of lipoxygenase products in the tumoral microenviron-
ment. In fact, the reduction of LTB4, an important
stimulator of chemiotaxis and cytotoxicity of macro-
phages [28–30], deprives host tissues of an efficient
defense against tumors. The depletion in the tumoral
microenvironment of another chemotactic factor for
monocytes [31–33], the lipoxins, may contribute to the
reduced resistance against tumor growth. Moreover,
the inhibition of lipoxygenase activity might favour
tumoral neoangiogenesis, in view of the recent finding
that a COX-2 product is converted by 5-lipoxygenase
into lipoxins with antiangiogenic activity [34]. Thus,
the block of synthesis of LTB4 and lipoxins in
macrophages upon contact with tumor cells might
represent a mechanism used by tumor cells to escape
from host defence. However, an opposite effect might
be produced by the disappearance of 12(S)-HETE from
the macrophage lipoxygenase profile. In fact, the block
of 12(S)-HETE generation by macrophages deprives
the tumoral microenvironment of a mediator which
promotes invasiveness by influencing various steps of
the ‘metastatic cascade’ [35]. Thus, the net effect of the
tumor-induced block of the macrophage lipoxygenase
pathway remains elusive. In view of the different
capacity of various anatomical compartments to
secrete lipoxygenase products of macrophages [36,
37], the effect of the tumor-induced block of the
macrophage lipoxygenase pathway on tumor growthmight depend on the lipoxygenase profile character-
istic of the tissue-specific macrophages.Acknowledgements
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